{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-068798","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.617943+00:00","generated_at":"2026-06-07T16:10:09.951073+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Axsome hosts solriamfetol investor day with expert panel covering MDD, ADHD, BED, and sleep disorders","bullets":["Virtual investor event held Dec 7, 2023, featuring five physician thought leaders discussing solriamfetol.","Indications covered: MDD, ADHD, binge eating disorder, OSA/EDS (SHARP study), and shift work disorder.","Axsome management provided overview of clinical development plans for solriamfetol.","No specific clinical data, financial results, or pipeline milestones disclosed in the press release."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-068798","json":"https://secwatch.observer/filing/0000950170-23-068798.json","markdown":"https://secwatch.observer/filing/0000950170-23-068798.md","text":"https://secwatch.observer/filing/0000950170-23-068798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/0000950170-23-068798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/axsm-20231207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:10:09.951073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}